SOLIRIS (eculizumab): The first treatment specifically approved for PNH

For US Healthcare Professionals

SOLIRIS and Fatigue Reduction

SOLIRIS markedly improves fatigue and maintains improvements over time

SOLIRIS and Fatigue Reduction

  • In the TRIUMPH clinical trial, improvements in fatigue began in the induction phase in SOLIRIS® (eculizumab)-treated patients and were maintained over the entire 26-week study3
     
  • In placebo-treated patients, fatigue levels worsened, despite receiving transfusions3
     
  • 78% of SOLIRIS-treated patients achieved clinically meaningful improvements in fatigue2
     

In the SHEPHERD study, patients who received SOLIRIS for 52 weeks also achieved significant improvements in fatigue as compared to baseline.4

SOLIRIS and Fatigue Reduction

SOLIRIS provides immediate improvements in fatigue that lasted throughout the duration of a year-long trial (52 weeks).1-4

Next: SOLIRIS and Patient Quality of Life

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS; revaccinate according to current medication guidelines for vaccine use.

Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.

References:
1. SOLIRIS® prescribing information. Alexion Pharmaceuticals, Inc. 2007.
2. Data on File. Alexion Pharmaceuticals, Inc.
3. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233-1243.
4. Young NS, Antonioli E, Rotoli B, et al. Safety and efficacy of the terminal complement inhibitor eculizumab in patients with paroxysmal nocturnal hemoglobinuria: interim SHEPHERD phase III clinical study. Poster and abstract presented at 2006 Annual Meeting of the American Society of Hematology. December 9-12, 2006. Orlando, FL.